Three senior executives of CRO Novella Clinical have assumed new leadership roles within the organization.
Deborah Turunjian has been named vice president, oncology clinical development and will lead further expansion of Novella's oncology division. Jamie Gault has been promoted to global head of regulatory affairs and will oversee preparation of regulatory packages for agencies globally. Kathleen Zajd has been named vice president, global quality and compliance.
Turunjian was executive leadership for Novella's business optimization and vendor management departments in addition to her oversight of western U.S. business operations. Turunjian brings over 30 years of leadership experience in business operations, overseeing global outsourcing and strategic partnerships in more than 25 countries. She has more than 10 years of operational management experience of phase I, II and III global oncology trials at both sponsors and CROs. Prior to Novella, Turunjian was director of clinical operations for OSI Pharmaceuticals.
Gault has 25 years experience in regulatory roles both at sponsors and CROs. Her regulatory authority interactions span drugs, biologics, cell and tissue-based products, combination products and medical devices. She has managed regulatory submissions including INDs, IDEs, NDAs and 510(k)s.
Zajd became a part of the Novella senior management team as a result of Novella's acquisition of Prologue Research International in 2010. Prior to co-founding Prologue, Zajd held leadership roles in clinical operations, regulatory and quality with experience spanning more than 25 years across both service organizations and sponsors. She has knowledge of GCPs/GLPs, ICH requirements and international directives/laws that govern the conduct of global clinical trials. With widespread experience conducting and managing domestic and international audit programs, she has also successfully established and maintained corporate quality management systems.